SEC Form 4 · accession 0001144204-16-105987
TITAN PHARMACEUTICALS INC · TTNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R McNab
Director
Period of report
May 31, 2016
Accepted (ET)
May 31, 2016 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000910267
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 31, 2016 | P | 20,000 | $7.03 | A | 100,000 | I | JR & MW Operating LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price for the reported transactions. The range of prices for such transactions was $6.96 to $7.14. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.